On the other hand, the placenta had sufficient expression of Oct3/Slc22, and some clinical studies reported that there were no significant differences in incidence of LGA, mean birthweight, and neonatal morbidity with metformin treatment and insulin treatment of GDM women [61,62]. The gene discussed is INS; the disease is gestational diabetes.